BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+(TM) at SITC 2025

Executive Summary

• BriaCell announced pre‑clinical evidence of strong innate and adaptive immune activation and durable anti‑cancer activity for its next‑generation Bria‑OTS+ platform, presented as a poster at the SITC 40th Anniversary Annual Meeting.
• The data highlight rapid tumor cell cytotoxicity for lead candidates Bria‑BRES+ (breast cancer) and Bria‑PROS+ (prostate cancer), supporting broad applicability across multiple solid‑tumor indications.
• Both candidates have completed GMP manufacturing and are slated for Phase 1/2a clinical evaluation, with Bria‑PROS+ backed by a $2 million NCI SBIR award.

Key Details

• Presentation: “Redefining Cancer Vaccines: Bria‑OTS+ Integrates Trained Innate Immunity and Adaptive Memory to Overcome Immune Resistance,” Abstract No. 353, SITC 2025 Annual Meeting, National Harbor, MD (Nov 7‑9, 2025).
• Preclinical Findings – Fast Acting: Bria‑BRES+ and Bria‑PROS+ rapidly activated key innate and adaptive immune components in animal models, leading to coordinated tumor cell killing.
• Preclinical Findings – Durable Response: Both candidates generated sustained anti‑cancer immune responses, suggesting potential for prolonged clinical benefit.
• Broad Applicability: Positive results support expansion of the Bria‑OTS+ platform into additional solid‑tumor indications beyond breast and prostate cancer.
• Manufacturing Status: GMP‑manufactured batches of Bria‑BRES+ and Bria‑PROS+ are complete and ready for upcoming clinical trials.
• Clinical Plans: Phase 1/2a studies for both candidates are planned; Bria‑PROS+ will be supported by a $2 million NCI SBIR award announced Aug 25, 2025.
• Poster Access: A copy of the poster will be available at https://briacell.com/scientific‑publications/.

Notable Quotes

“We are thrilled with the comprehensive, powerful, and long‑lasting immune activation demonstrated by Bria‑OTS+ in our preclinical studies… we believe will translate into meaningful anti‑cancer immune responses in the clinic.” – Miguel A. Lopez‑Lago, PhD, Chief Scientific Officer

“These findings add to the growing body of evidence supporting our Bria‑OTS+ platform’s unique mechanism of action for novel personalized cancer immunotherapies… we look forward to confirming these encouraging preclinical results in planned clinical trials.” – Dr. William V. Williams, President & CEO